

**Methyl 2-(2-{1-[3-(3,5-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-2-(dimethylamino)-vinyloxy}phenyl)-3-(dimethylamino)acrylate****Jia-Hui Chen,\* Hai-Bo Wang,  
Yue-Qing Pu and Jin-Tang Wang**

Department of Applied Chemistry, College of Science, Nanjing University of Technology, Xinmofan Road No. 5, Nanjing 210009, People's Republic of China


Correspondence e-mail:  
wanghaibo@njut.edu.cn**Key indicators**Single-crystal X-ray study  
 $T = 293\text{ K}$   
Mean  $\sigma(\text{C}-\text{C}) = 0.007\text{ \AA}$   
 $R$  factor = 0.072  
 $wR$  factor = 0.261  
Data-to-parameter ratio = 15.5For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

The title compound,  $C_{26}H_{30}N_4O_6$ , was synthesized by the reaction of methyl (2-[[3-(3,5-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]methoxy]phenyl)acetate and *N,N*-dimethylformamide dimethyl acetal. In the molecular structure, there are intramolecular  $\text{C}-\text{H}\cdots\text{O}$  and  $\text{C}-\text{H}\cdots\text{N}$  hydrogen bonds, and also intermolecular  $\text{C}-\text{H}\cdots\pi$  and  $\text{C}-\text{H}\cdots\text{O}$  interactions.


Received 1 October 2004  
Accepted 14 October 2004  
Online 22 October 2004**Comment**

1,2,4-Oxadiazoles represent an important class of five-membered heterocycles. Some derivatives of 1,2,4-oxadiazoles have intrinsic analgesic (Terashita *et al.*, 2002), anti-inflammatory (Nicolaides *et al.*, 1998) and antipicornaviral (Romero, 2001) properties and are efficient as agonists [*e.g.* for angiotensin (Naka & Kubo, 1999) and adhesion (Juraszyk *et al.*, 1997)] for different receptors.


We report here the crystal structure of the title compound, (I). The molecular structure of (I) is shown in Fig. 1; dashed lines indicate intramolecular  $\text{C}-\text{H}\cdots\text{N}$  and  $\text{C}-\text{H}\cdots\text{O}$  hydrogen bonds (Table 2). Selected bond lengths and angles are given in Table 1. There are also intermolecular contacts, which indicate weak  $\text{C}-\text{H}\cdots\pi$  interactions (Fig. 2) and  $\text{C}-\text{H}\cdots\text{O}$  hydrogen bonds (Fig. 3). Full details of the hydrogen bonding are given in Table 2. The combination of both types of weak interactions generates a three-dimensional network.

**Experimental**


Methyl (2-[[3-(3,5-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]methoxy]phenyl) acetate (14 mmol) was dissolved in DMF (20 ml) and *N,N*-dimethylformamide dimethyl acetal (8 ml) was added in one portion. The resulting mixture was refluxed for 6 h, and then concentrated under reduced pressure to afford crude compound (I). Pure compound (I) was obtained by crystallization from ethyl acetate (15 ml) and petroleum ether (7.5 ml). Crystals of (I) suitable for

**Figure 1**

A view of the molecular structure of (I). Dashed lines indicate intramolecular C–H···N and C–H···O hydrogen bonds. Displacement ellipsoids are drawn at the 30% probability level.

**Figure 3**


Short C–H···O contacts in (I), shown as dashed lines.

**Figure 2**

C–H···π interactions in (I), shown as dashed lines.

X-ray diffraction were obtained by slow evaporation of an ethanol solution.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , p.p.m.):  $\delta$  7.69 (*m*, 1H), 7.33 (*m*, 1H), 7.15–7.26 (*m*, 4H), 6.94–6.95 (*m*, 1H), 6.87–6.89 (*m*, 1H), 6.54 (*m*, 1H), 3.81 (*s*, 6H), 3.56 (*s*, 3H), 3.01 (*s*, 6H), 2.85 (*m*, 6H).

#### Crystal data



$M_r = 494.54$

Triclinic,  $\overline{P}1$

$a = 8.6500$  (17) Å

$b = 10.700$  (2) Å

$c = 14.817$  (3) Å

$\alpha = 107.66$  (3)°

$\beta = 97.50$  (3)°

$\gamma = 95.15$  (3)°

$V = 1283.4$  (4) Å<sup>3</sup>

$Z = 2$

$D_x = 1.280 \text{ Mg m}^{-3}$

Mo  $K\alpha$  radiation

Cell parameters from 25 reflections

$\theta = 9\text{--}12^\circ$

$\mu = 0.09 \text{ mm}^{-1}$

$T = 293$  (2) K

Block, colourless

$0.3 \times 0.2 \times 0.1$  mm

#### Data collection

Enraf–Nonius CAD-4 diffractometer

$\omega/2\theta$  scans

Absorption correction: none

5386 measured reflections

5030 independent reflections

2308 reflections with  $I > 2\sigma(I)$

$R_{\text{int}} = 0.051$

$\theta_{\text{max}} = 26.0^\circ$

$h = 0 \rightarrow 10$

$k = -13 \rightarrow 13$

$l = -18 \rightarrow 18$

3 standard reflections every 200 reflections

intensity decay: none

#### Refinement

Refinement on  $F^2$

$R[F^2 > 2\sigma(F^2)] = 0.072$

$wR(F^2) = 0.261$

$S = 1.04$

5030 reflections

325 parameters

H-atom parameters constrained

$$w = 1/\left[\sigma^2(F_o^2) + (0.13P)^2\right]$$

where  $P = (F_o^2 + 2F_c^2)/3$

$$(\Delta/\sigma)_{\text{max}} = 0.001$$

$$\Delta\rho_{\text{max}} = 0.30 \text{ e } \text{\AA}^{-3}$$

$$\Delta\rho_{\text{min}} = -0.31 \text{ e } \text{\AA}^{-3}$$

**Table 1**  
Selected geometric parameters (Å, °).

O4—C10	1.380 (5)	C19—N3	1.333 (5)
O4—C9	1.400 (5)	N3—C21	1.435 (6)
O3—C8	1.340 (5)	N3—C20	1.453 (6)
O3—N1	1.423 (4)	O6—C17	1.367 (6)
N2—C8	1.311 (5)	O6—C18	1.424 (6)
N2—C7	1.380 (5)	N4—C22	1.312 (6)
C4—C7	1.460 (6)	N4—C24	1.430 (6)
C8—C9	1.427 (6)	N4—C23	1.466 (6)
C7—N1	1.305 (5)	C16—C22	1.380 (7)
C15—C16	1.491 (6)	C16—C17	1.436 (7)
C9—C19	1.353 (6)	O5—C17	1.206 (6)
C10—O4—C9	116.1 (3)	N3—C19—C9	131.9 (4)
C8—O3—N1	106.4 (3)	C19—N3—C21	121.2 (4)
C8—N2—C7	102.4 (3)	C19—N3—C20	123.9 (4)
O2—C2—C1	124.2 (4)	C21—N3—C20	114.8 (4)
C5—C4—C7	120.3 (4)	C17—O6—C18	116.0 (5)
N2—C8—O3	113.2 (4)	C22—N4—C24	126.6 (5)
N2—C8—C9	129.7 (4)	C22—N4—C23	119.1 (5)
O3—C8—C9	117.1 (4)	C24—N4—C23	114.3 (5)
N1—C7—N2	114.9 (4)	O1—C6—C1	124.1 (4)
N1—C7—C4	120.9 (4)	C22—C16—C17	114.9 (4)
N2—C7—C4	124.2 (4)	C22—C16—C15	125.2 (4)
C7—N1—O3	103.1 (3)	C17—C16—C15	119.8 (4)
C10—C15—C16	120.6 (4)	O5—C17—O6	120.6 (5)
C11—C10—O4	123.7 (4)	O5—C17—C16	128.2 (6)
C19—C9—O4	123.7 (4)	O6—C17—C16	111.2 (4)
C19—C9—C8	120.5 (4)		

**Table 2**  
Hydrogen-bonding geometry ( $\text{\AA}$ ,  $^\circ$ ).

$D-\text{H}\cdots A$	$D-\text{H}$	$\text{H}\cdots A$	$D\cdots A$	$D-\text{H}\cdots A$
C5—H5A···N2	0.93	2.62	2.933 (5)	100
C19—H19A···N2	0.93	2.59	2.960 (5)	104
C20—H20A···O4	0.96	2.17	2.943 (5)	136
C22—H22A···O5	0.93	2.38	2.780 (6)	106
C20—H20B···Cg1 <sup>i</sup>	0.96	2.98	3.921 (6)	169
C26—H26C···Cg2 <sup>ii</sup>	0.96	2.91	3.723 (5)	143
C23—H23A···O5 <sup>iii</sup>	0.96	2.43	3.362 (7)	162
C23—H23B···O2 <sup>iv</sup>	0.96	2.56	3.339 (7)	138
C24—H24C···O2 <sup>iv</sup>	0.96	2.52	3.305 (7)	139

Symmetry codes: (i)  $-x, 1 - y, 1 - z$ ; (ii)  $-1 - x, 1 - y, 2 - z$ ; (iii)  $-x, 2 - y, 1 - z$ ; (iv)  $-x, 2 - y, 2 - z$ . Cg1 and Cg2 are the centroid of the O3/N1/C7/N2/C8 and C1—C6 rings, respectively.

All H were positioned geometrically with C—H distances of 0.93–0.96  $\text{\AA}$  and included in the refinement in the riding-model approximation, with  $U_{\text{iso}}(\text{H}) = 1.2$  or  $1.5U_{\text{eq}}(\text{C})$ .

Data collection: *CAD-4 Software* (Enraf–Nonius, 1989); cell refinement: *CAD-4 Software*; data reduction: *XCAD4* (Harms & Wocadlo, 1995); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *SHELXTL* (Siemens, 1996); software used to prepare material for publication: *SHELXL97*.

## References

- Enraf–Nonius (1989). *CAD-4 Software*. Version 5.0. Enraf–Nonius, Delft, The Netherlands.
- Harms, K. & Wocadlo, S. (1995). *XCAD4*. University of Marburg, Germany.
- Juraszyk, H., Gante, J., Wurziger, H., Bernotat-Danielowski, S. & Melzer, G. (1997). *PCT Int. Appl.* 9744333.
- Naka, T. & Kubo, K. (1999). *Curr. Pharm. Des.* **5**, 453–472.
- Nicolaides, D. N., Fylaktakidou, K. C., Litinas, K. E. & Hadjipavlou-Litina, D. (1998). *Eur. J. Med. Chem.* **33**, 715–724.
- Romero, J. R. (2001). *Expert Opin. Invest. Drugs*, **10**, 369–379.
- Sheldrick, G. M. (1997). *SHELXL97* and *SHELXS97*. University of Göttingen, Germany.
- Siemens (1996). *SHELXTL*. Version 5.06. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
- Terashita, Z., Naruo, K. & Morimoto, S. (2002). *PCT Int. Appl.* WO 0260439.